Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525076-29-00

Enrollment

Registered

2026-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney or heart allograft recipients and for treatment of allograft rejection, Phase I study in healthy male volunteers. Intended indication: prophylaxis of transplant rejection in liver

Interventions

None listed

Eligibility

Sex/Gender

Male

Age

18 Years to 64 Years

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 5, 2026

Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).

Conditions

Related papers

Interventions

Sponsors

Eligibility

Outcome results